NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading HRTX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround scenario. HRTX is currently struggling with losses and declining revenue, but it operates within a healthcare sector that is experiencing positive momentum.
The market seems to have priced in a cautious outlook given the company's recent earnings miss and ongoing legal issues. However, the sector's overall strength may provide some support, suggesting that expectations are mixed.
Management has reaffirmed revenue and EBITDA targets for 2026, but recent results show a decline in revenue and worsening operating income. The fundamentals are likely to remain under pressure in the near term, with a significant risk of missing guidance.
The long-term thesis hinges on whether HRTX can achieve its revenue and EBITDA targets while navigating legal challenges. Additionally, the performance of sector bellwethers like VRTX, REGN, and ARGX will be crucial in determining the overall momentum in the healthcare sector.
HRTX's outlook is uncertain as it grapples with operational losses and external pressures. The next few quarters will be critical in assessing its recovery potential. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or beating revenue guidance is key for investor trust and future growth.
Confirms:Q2 2026 total net revenue reported at or above $173 million.
Disproves:Q2 2026 total net revenue reported below $173 million.
Why it matters: The delisting notice might hurt investor confidence. It could also lower the stock price.
Confirms:The company provides a plan to regain compliance with Nasdaq listing standards.
Disproves:No plan is communicated, or the stock price remains below $1.00 for another 30 days.
Why it matters: Better operating income is key for long-term success. A good trend can help investor trust.
Confirms:Operating income was more than -$4.8 million.
Disproves:Operating income was worse than -$4.8 million.
Why it matters: Hitting this EBITDA target would show better financial health. It also means better operations.
Confirms:Adjusted EBITDA is between $10 million and $20 million. This is within the target range.
Disproves:Adjusted EBITDA is still negative or under $10 million. This shows continued losses.
Why it matters: Meeting or exceeding this target is key to achieving full-year revenue guidance. It shows the company is on track despite recent declines.
Confirms:Q2 revenue reported at or above $40 million.
Disproves:Q2 revenue reported below $34.7 million.
Why it matters: The result of this lawsuit may change Heron's market position and revenue from CINVANTI.
Confirms:Heron gets a good ruling in the lawsuit.
Disproves:A ruling against Heron lets Slayback make a generic CINVANTI.
